3 completed, 2 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Celtic Pharma Development Services: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multisite Controlled Trial of Cocaine Vaccine TA-CD Vaccination, Placebo Injection - Cocaine Dependence | Phase 2 | Completed | Baylor College of Medicine | 300 | 2010-08-01 | 2017-03-15 |
| Tolerability Study of Xerecept® in Pediatric Patients XERECEPT - Brain Edema, Brain Tumor | Phase 1 / Phase 2 | Terminated | Celtic Pharma Development Services | 15 | 2010-06-01 | 2013-07-30 |
| TDT 067 Open Label Multi-Dose Onychomycosis Study TDT067 and Lamisil - Onychomycosis | Phase 2 | Completed | Celtic Pharma Development Services | 27 | 2009-12-01 | 2013-02-13 |
| Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE) Xerecept - Peritumoral Brain Edema, PRIMARY MALIGNANT and METASTATIC BRAIN TUMORS | Phase 2 | Terminated | PharmaNet | 60 | 2008-11-01 | 2009-01-09 |
| Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation TA-NIC, Placebo - Smoking | Phase 2 | Completed | Celtic Pharma Development Services | 522 | 2007-05-01 | 2011-06-08 |
Brain Neoplasms (2) · Brain Edema (1) · Cocaine-Related Disorders (1) · Edema (1) · Onychomycosis (1) · Smoking (1) · Smoking Cessation (1)
Corticotropin-Releasing Hormone (1) · TA-NIC (1) · Terbinafine (1)
United States (3)
Eduardo Tschen, MD (1) · Stewart Goldman, MD (1) · Thomas R Kosten, M.D. (1)
R01DA025223 (1)